Solid Tumors with Specific Mutations

- **IDH 1/2 mutant**
  - **10129:** A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors

- **CCNE1 amplification**
  - **10136:** A Phase 2 Trial of AZD1775, a Wee1 Inhibitor, in Patients with CCNE1 Amplification

- **PTEN, PIK3CA**
  - **10131:** Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel (Expansion: breast, prostate, other solid tumors)

- **DNA repair; PI3K/AKT; RAS/RAF/MEK**
  - **10222:** Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH)-Mutant Solid Tumors
  - **10136:** A Phase 2 Trial of AZD1775, a Wee1 Inhibitor, in Patients with CCNE1 Amplification
  - **10131:** Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel (Expansion: breast, prostate, other solid tumors)

- **NF1, KEAP1, and LKB1**
  - **10217:** A Phase 1b Biomarker-Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients with Advanced Solid Tumors (Expansion: germline or and somatic DDR aberrations; PIK3CA mutant; PTEN loss)
  - **10220:** A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors

- **Loss of SETD2**
  - **10170:** A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies

- **NUT fusion oncogene**
  - **10220:** A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors
  - **10295:** A Phase 1/2 Study of the Bromodomain Inhibitor Molibresib in Combination with Etoposide/Platinum in Patients with NUT Carcinoma

---

**NOTE:** * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: July 15, 2019